ICU
Price
$2.51
Change
+$0.04 (+1.62%)
Updated
Oct 27, 10:52 AM (EDT)
Capitalization
10.88M
16 days until earnings call
Intraday BUY SELL Signals
TNXP
Price
$5.38
Change
+$0.09 (+1.70%)
Updated
Oct 27, 11:12 AM (EDT)
Capitalization
90.9M
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ICU vs TNXP

ICU vs TNXP Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ICU vs. TNXP commentary
Oct 27, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICU is a StrongBuy and TNXP is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ICU with price predictions
Oct 26, 2026

ICU in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 23, 2026

ICU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 39 cases where ICU's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +10.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICU advanced for three days, in 147 of 182 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 84 of 147 cases where ICU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.

Bearish Trend Analysis

The 10-day RSI Indicator for ICU moved out of overbought territory on October 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 19 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.

The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICU as a result. In 76 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for ICU turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 32 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.

ICU moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ICU crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

The 50-day moving average for ICU moved below the 200-day moving average on October 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.534) is normal, around the industry mean (3.037). P/E Ratio (-1.307) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (6.468) is also within normal values, averaging (439.237).

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ICU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for TNXP with price predictions
Oct 26, 2026

TNXP in +3.31% Uptrend, advancing for three consecutive days on October 26, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TNXP advanced for three days, in 180 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

TNXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day moving average for TNXP crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNXP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TNXP entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.409) is normal, around the industry mean (3.037). P/E Ratio (-0.405) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (5.176) is also within normal values, averaging (439.237).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. TNXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
TNXP: Fundamental Ratings
TNXP
OUTLOOK RATING
1..100
5
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ICUTNXP
RSI
ODDS (%)
Bearish Trend 2 days ago
68%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
70%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 16 days ago
81%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
57%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 27, 2026
Stock price -- (ICU: $2.47 vs. TNXP: $5.30)
Brand notoriety: ICU and TNXP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ICU: 80% vs. TNXP: 87%
Market capitalization -- ICU: $10.88M vs. TNXP: $90.9M
ICU [@Biotechnology] is valued at $10.88M. TNXP’s [@Biotechnology] market capitalization is $90.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $131.16B. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ICU’s FA Score shows that 1 FA rating(s) are green while TNXP’s FA Score has 0 green FA rating(s).

  • ICU’s FA Score: 1 green, 4 red.
  • TNXP’s FA Score: 0 green, 5 red.
According to our system of comparison, ICU is a better buy in the long-term than TNXP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ICU’s TA Score shows that 4 TA indicator(s) are bullish while TNXP’s TA Score has 2 bullish TA indicator(s).

  • ICU’s TA Score: 4 bullish, 7 bearish.
  • TNXP’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, TNXP is a better buy in the short-term than ICU.

Price Growth

ICU (@Biotechnology) experienced а -20.58% price change this week, while TNXP (@Biotechnology) price change was -7.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.32%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -13.52%.

Reported Earning Dates

ICU is expected to report earnings on Nov 12, 2026.

TNXP is expected to report earnings on Nov 09, 2026.

Industries' Descriptions

@Biotechnology (+4.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ICU
Daily Signal:
Gain/Loss:
TNXP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ICU and

Correlation & Price change

A.I.dvisor indicates that over the last year, ICU has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if ICU jumps, then CANF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICU
1D Price
Change %
ICU100%
+2.49%
CANF - ICU
93%
Closely correlated
-3.37%
APVO - ICU
85%
Closely correlated
-6.25%
GNPX - ICU
82%
Closely correlated
N/A
TNXP - ICU
77%
Closely correlated
+2.51%
LONA - ICU
62%
Loosely correlated
-1.65%
More

TNXP and

Correlation & Price change

A.I.dvisor indicates that over the last year, TNXP has been closely correlated with ICU. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if TNXP jumps, then ICU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TNXP
1D Price
Change %
TNXP100%
+2.51%
ICU - TNXP
77%
Closely correlated
+2.49%
CADL - TNXP
42%
Loosely correlated
-2.99%
ZURA - TNXP
40%
Loosely correlated
+5.95%
ABSI - TNXP
40%
Loosely correlated
+2.94%
TSHA - TNXP
40%
Loosely correlated
+1.26%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GOEX72.810.50
+0.69%
Global X Gold Explorers ETF (GOEX)
RXD13.170.04
+0.28%
ProShares UltraShort Health Care (RXD)
GFGF35.41N/A
N/A
Guru Favorite Stocks ETF (GFGF)
BIDD28.82-0.02
-0.07%
iShares International Dividend Active ETF (BIDD)
USO166.23-3.30
-1.95%
United States Oil Fund LP (USO)